公开(公告)号：US20040013643A1

公开(公告)日：2004-01-22

申请号：US10349549

申请日：2003-01-22

Applicant: Novlmmune S.A.

Inventor： Francois Mach

IPC: A61K038/21 ,  A61K031/65 ,  A61K031/59 ,  A61K031/505 ,  A61K031/401 ,  A61K031/366 ,  A61K031/557 ,  A61K031/35

CPC classification number: A61K31/366 ,  A61K31/225 ,  A61K31/401 ,  A61K45/06 ,  H01J9/025 ,  H01J29/02 ,  H01J2201/319 ,  H01J2329/00

Abstract: New uses of statins as novel types of immunomodulator. More specifically, the invention relates to methods for treating multiple sclerosis through the administration of one or more statins, and even more advantageously, in combination with other multiple sclerosis agents or treatments, such as null-interferons or copaxone.

Abstract translation: 他汀类药物的新用途是新型免疫调节剂。 更具体地，本发明涉及通过施用一种或多种他汀类药物治疗多发性硬化的方法，甚至更有利地与其它多发性硬化症药物或治疗剂如β-干扰素或copaxone组合治疗。

公开(公告)号：US20020156122A1

公开(公告)日：2002-10-24

申请号：US09960471

申请日：2001-09-19

Applicant: Novlmmune S.A.

Inventor： Francois Mach

IPC: A61K031/401 ,  A61K031/366 ,  A61K031/225

CPC classification number: A61K31/225 ,  A61K31/22 ,  A61K31/365 ,  A61K31/366 ,  A61K31/40 ,  A61K31/401 ,  A61K31/404

Abstract: The present invention relates to methods of causing MHC-class II or CD40 mediated immunomodulation, immunosuppression and anti-inflammatory action, in a subject suffering from or susceptible of suffering ftom a condition involving inappropriate immune response, which comprises administering to the subject at least one statin, or a functionally or structurally equivalent molecule, in an amount effective to modulate MHC class II or CD40 expression in the subject.

Abstract translation: 本发明涉及在患有或易患有涉及不适当的免疫应答的病症的受试者中引起MHC-II类或CD40介导的免疫调节，免疫抑制和抗炎作用的方法，其包括向受试者施用至少一种 他汀类或功能上或结构上等同的分子，其量可以有效调节受试者中的MHC II类或CD40表达。